Adjuvant monoarthritis was induced by the injection of 50μl Complete Freund's Adjuvant（CFA) into ankle joint of adult SD rats. Electroacupuncture (EA)was performed on Huantiao (GB30)and Yanglingquan (GB 34) (0.5...Adjuvant monoarthritis was induced by the injection of 50μl Complete Freund's Adjuvant（CFA) into ankle joint of adult SD rats. Electroacupuncture (EA)was performed on Huantiao (GB30)and Yanglingquan (GB 34) (0.5-1.5 v, 4-16 Hz, 30 min) after the injection.展开更多
Recently,the substance P(SP)/neurokinin-1 receptor(NK-1R)system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019(COVID-19).Besides,studies ...Recently,the substance P(SP)/neurokinin-1 receptor(NK-1R)system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019(COVID-19).Besides,studies in the oncological field have demonstrated an intricate correlation between the upregulation of NK-1R and the activation of SP/NK-1R system with the progression of multiple carcinoma types and poor clinical prognosis.These findings indicate that the modulation of SP/NK-1R system with NK-1R antagonists can be a potential broad-spectrum antitumor strategy.This review updates the latest potential and applications of NK-1R antagonists in the treatment of human diseases and cancers,as well as the underlying mechanisms.Furthermore,the strategies to improve the bioavailability and efficacy of NK-1R antagonist drugs are summarized,such as solid dispersion systems,nanonization,and nanoencapsulation.As a radiopharmaceutical therapeutic,the NK-1R antagonist aprepitant was originally developed as radioligand receptor to target NK-1R-overexpressing tumors.However,combining NK-1R antagonists with other drugs can produce a synergistic effect,thereby enhancing the therapeutic effect,alleviating the symptoms,and improving patients’quality of life in several diseases and cancers.展开更多
文摘Adjuvant monoarthritis was induced by the injection of 50μl Complete Freund's Adjuvant（CFA) into ankle joint of adult SD rats. Electroacupuncture (EA)was performed on Huantiao (GB30)and Yanglingquan (GB 34) (0.5-1.5 v, 4-16 Hz, 30 min) after the injection.
基金This work was supported by the Zhejiang Provincial Natural Science Foundation of China(No.LD22H310004)the“Pioneer”and“Leading Goose”R&D Program of Zhejiang(No.2022C03005),China.
文摘Recently,the substance P(SP)/neurokinin-1 receptor(NK-1R)system has been found to be involved in various human pathophysiological disorders including the symptoms of coronavirus disease 2019(COVID-19).Besides,studies in the oncological field have demonstrated an intricate correlation between the upregulation of NK-1R and the activation of SP/NK-1R system with the progression of multiple carcinoma types and poor clinical prognosis.These findings indicate that the modulation of SP/NK-1R system with NK-1R antagonists can be a potential broad-spectrum antitumor strategy.This review updates the latest potential and applications of NK-1R antagonists in the treatment of human diseases and cancers,as well as the underlying mechanisms.Furthermore,the strategies to improve the bioavailability and efficacy of NK-1R antagonist drugs are summarized,such as solid dispersion systems,nanonization,and nanoencapsulation.As a radiopharmaceutical therapeutic,the NK-1R antagonist aprepitant was originally developed as radioligand receptor to target NK-1R-overexpressing tumors.However,combining NK-1R antagonists with other drugs can produce a synergistic effect,thereby enhancing the therapeutic effect,alleviating the symptoms,and improving patients’quality of life in several diseases and cancers.
